Company
Headquarters: San Diego, CA, United States
Employees: 17
CEO: Dr. Brian Lian Ph.D.
$3.17 Billion
USD as of July 1, 2025
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $309.91 B |
Vertex Pharmaceuticals Incorporated | $117.36 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $59.14 B |
Marinomed Biotech AG | $58.56 B |
Company | Market Cap (USD) |
---|---|
Lilly | $699.59 B |
Johnson & Johnson | $374.29 B |
AbbVie | $336.94 B |
Novo Nordisk | $309.91 B |
UnitedHealth Group | $279.90 B |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRà), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRà for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Last Financial Reports Date | March 31, 2025 |
Revenue TTM | $0 |
EBITDA | $0 |
Gross Profit TTM | $0 |
Profit Margin | 0.00% |
Operating Margin | 0.00% |
Quarterly Revenue Growth | % |
Viking Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: VKTX wb_incandescent
Stock: FSX: 1VT wb_incandescent